spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

c-LEcta signs Europe sales and distribution agreement with VWR for c-LEcta’s DENARASE®


• DENARASE® is now available through VWR’s sales channels in Europe
• VWR, part of Avantor, is a leading global provider of product and service solutions to laboratory and production customers
• Cooperation harbors the potential for c-LEcta’s product to gain additional share in a highly dynamic market

c-LEcta, a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma, signs a European sales and distribution agreement for its DENARASE® with VWR, part of Avantor. The high quality and highly active nuclease enzyme offers more efficient solutions for the removal of genetic information carriers (nucleic acids; DNA and RNA) in biopharmaceutical processes to pharmaceutical manufacturers. The availability and distribution of DENARASE® via VWR’s well established European channels harbors the potential for c-LEcta’s product to gain additional share in a highly dynamic market.

DENARASE® helps to remove nucleic acids from many applications of red biotechnology and molecular biology to be marketable and to comply with regulatory requirements under lucrative and more biocompatible conditions. It has proven to be robust under demanding process conditions and quantitatively removes interfering host cell DNA and RNA from fermentation batches, e.g. during the production of vaccines and biopharmaceuticals. The complete removal of nucleic acids from pharmaceutical products is a strict regulatory demand. Furthermore, the handling of process liquids (e.g. in filtration or chromatography) can be considerably simplified and the follow-up costs reduced to a competitive level. Therefore, DENARASE® is the ideal choice for pharmaceutical manufacturers to optimize process efficiencies and improve product recovery rates for the production of safe and compliant pharmaceutical products.

DENARASE®is manufactured using a patent protected production process based on the recombinant expression in an endotoxin-free Bacillus production host. The manufacturing process does avoid the use of raw material of animal origin and antibiotics and is run in full compliance with cGMP (current Good Manufacturing Practice) requirements.

"We are very pleased to announce our distribution agreement with VWR, part of Avantor, to provide yet even better services to our valued customers in Europe" says Cord von Limburg, Head of Sales at c-LEcta. "There is a substantial opportunity here to gain additional share in what is a highly dynamic market. By partnering with VWR we believe that the combination of our product innovation and their reputation for service and quality will further develop c LEcta´s customer base.”

Based on this agreement, DENARASE® will now be available through vwr.com and all other regular VWR sales channels in Europe.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>


White Papers

Competitive Drive: The Challenges of a Globalised Packaging Industry

Aesica Pharmaceuticals

Packaging is becoming an increasingly competitive and lucrative industry globally. Jeremy Drummond PhD of Aesica Formulated Products looks at the challenges and opportunities this presents.
More info >>

Industry Events

14th Annual Biomarkers Congress

21-22 February 2019, Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 – 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement